Skip to main content

Jerm Day-Storms, PhD, MWC

Authored Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Jerm Day-Storms, PhD, MWC
December 2023 Vol 16, Payers' Guide to FDA Updates in In-Depth Drug Profile
Exa-cel and Lovo-cel Provide Potential Functional Cure for Patients with SCD or TDT
Jerm Day-Storms, PhD, MWC
December 2023 Vol 16, Payers' Guide to FDA Updates in In-Depth Drug Profile
IMJUDO (Tremelimumab-actl) in Combination With IMFINZI (Durvalumab) Receives FDA Approval for HCC and NSCLC
Jerm Day-Storms, PhD, MWC
September 2023 Vol 16, Payers' Guide to FDA Updates in FDA Approvals
FDA Approval of SYFOVRE (Pegcetacoplan) and IZERVAY (Avacincaptad Pegol) Reshapes Management of GA
Jerm Day-Storms, PhD, MWC
September 2023 Vol 16, Payers' Guide to FDA Updates in FDA Approvals
Last modified: October 7, 2023